Skip to content

Rheumatoid arthritis

The current guideline is the EULAR 2025 update on synthetic and biological DMARDs. It simplifies the 2022 algorithm: after methotrexate fails, everyone gets a biologic (JAK inhibitors only after a risk assessment).

EULAR 2025

International Current

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2025 update

Official source

Clinical pearls

  • Window of opportunity: start a DMARD at diagnosis.
  • MTX + short-term steroids, review at 3 months, target by 6 months.
  • Treat to target: remission (Boolean or SDAI ≤3.3 / CDAI ≤2.8) or low disease activity.
  • JAK inhibitors: caution if over 65, a smoker, or with CV, cancer or VTE risk.